Relapsed or Refractory Multiple Myeloma (RRMM)
Oncology·MeSH: Multiple Myeloma
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
10 drugs in development·5 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(4)
Phase 1(1)
| Drug | Company |
|---|---|
| ACLX-001 | Arcellx, Inc. (ACLX) |
Phase 1/Phase 2(4)
Phase 4(1)
| Drug | Company |
|---|---|
| BMS-986393 | BRISTOL MYERS SQUIBB CO (BMY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed or Refractory Multiple Myeloma (RRMM)?
BioSniper tracks 10 drugs in development for Relapsed or Refractory Multiple Myeloma (RRMM) across 5 companies.
How many clinical trials target Relapsed or Refractory Multiple Myeloma (RRMM)?
There are 2 clinical trials targeting Relapsed or Refractory Multiple Myeloma (RRMM) tracked by BioSniper.
What is the prevalence of Relapsed or Refractory Multiple Myeloma (RRMM)?
The estimated prevalence of Relapsed or Refractory Multiple Myeloma (RRMM) is approximately 17.0 per 100,000 population.
Deep-dive into Relapsed or Refractory Multiple Myeloma (RRMM)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis